MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function
NCT03606538
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Pharmacokinetics
Hepatic Impairment
Interventions
DRUG:
Midomafetamine HCl
Sponsor
Resilient Pharmaceuticals